We're celebrating
40 years!
Last updated:
April 11, 2008
Years published: 1988, 1989, 1993, 1997, 1999, 2004, 2005
NORD gratefully acknowledges the members of the Medical and Scientific Advisory Board of the Foundation for Ichthyosis & Related Skin Types for assistance in the preparation of this report.
Netherton syndrome is a rare hereditary disorder characterized by scaling skin, hair anomalies, increased susceptibility to atopic eczema (a skin condition that can result in dry, red and flaky skin), elevated IgE levels, and other related symptoms. Netherton syndrome is inherited as an autosomal recessive trait.
Newborns with Netherton syndrome have reddened skin (erythroderma) and sometimes a thick parchment-like covering of skin (collodion membrane). The skin is red and scaly all over. Hair shafts are fragile and break easily due to trichorrhexis or “bamboo hair”, resulting in short sparse hair. In older children and adults the scaling may have a distinctive circular pattern (ichthyosis linearis circumflexa). Another characteristic of Netherton syndrome is a predisposition to allergies, asthma, and eczema.
Babies with Netherton syndrome may be born prematurely. Trouble gaining weight in infancy and childhood is common and can be severe. Infants may also have recurrent skin infections and septicemia. They may develop hypernatremia (elevated sodium levels in the blood) due to excessive loss of fluid from the skin surface. Because hairs may not be affected at birth, and then may be sparse in all babies in the first months of life, the characteristic hair defect that is diagnostic of Netherton syndrome may not be detected initially.
Infants with Netherton syndrome may be misdiagnosed as having CIE (congenital ichthyosiform erythroderma), atopic dermatitis or psoriasis. Atopic dermatitis (red, itchy patches of skin) may be present and a cradle cap-like scale and redness may appear on the face, scalp and eyebrows.
The mutation that causes Netherton syndrome has been pinpointed to the gene SPINK5 located on the long arm (q) of chromosome 5 (5q32). This mutation is transmitted by autosomal recessive inheritance. Individuals must inherit two recessive genes in order to show the disorder, with each parent donating one mutated gene. The parents (carriers) show no evidence of Netherton syndrome.
The SPINK5 gene encodes a protein that serves as the brake on the activity of certain proteases (enzymes that digest proteins) in the skin protein. Increased protease action in the skin results in too few layers of the outer skin (stratum corneum), not in too many layers as in other forms of ichthyosis.
Netherton syndrome is a rare hereditary disorder. There are approximately 150 cases reported in the medical literature, but the true number of affected individuals may be much higher due to diagnostic difficulties and overlapping symptoms with common atopic dermatitis and other congenital ichthyoses.
The treatment of Netherton syndrome is symptomatic, often difficult, and should be tailored to the patient's specific needs. Recommendations include the regular use of emollients and moisturizing creams and lotions. Other topical agents should be used with caution because the skin in Netherton syndrome may allow ingredients from some topically applied medications to be absorbed into the blood, which may pose a danger to the child. Topical keratolytic agents such as urea or lactic acid derivatives may be limited by skin irritation and should generally be reserved for older children. The base line treatment also includes oral antihistamines, which can help to control the itchy, eczematous component, and topical or systemic antibiotics as needed. To treat the scaling of the scalp, mild dandruff shampoos and topical steroids might be helpful. Oral and topical steroids are beneficial in reducing inflammation and the eczematous component of the disease. However, the well-documented side effects of long-term steroid use need to be considered. Oral retinoids have been used with varying success, leading to dramatic improvement in some patients and severe worsening of the disease in others.
Molecular Diagnostic testing for Netherton syndrome is offered by:
Gabriele Richard, MD
Associate Professor, Department of Dermatology and Cutaneous Biology and
Department of Medicine / Division of Medical Genetics
Thomas Jefferson Unversity
233 S. 10th. Street, BLSB Suite 409
Philadelphia, PA 19107
Telephone: ( 215) 503-8259 (lab)
Fax: (215) 503-5788
Email. Gabriele.Richard@jefferson.edu
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov
For information about clinical trials sponsored by private sources, contact:
www.centerwatch.com
Researchers have studied the use of calcipotriol, a vitamin D derivative, as a potential treatment for individuals with Netherton syndrome. In one case, the initial results demonstrated improvement of erythema and scaling and no adverse effects. More research is necessary to determine the long-term safety and effectiveness of this potential treatment for Netherton syndrome.
JOURNAL ARTICLES
Chao SC, Richard G, Lee JY. Netherton syndrome: report of two Taiwanese siblings with staphylococcal scalded skin syndrome and mutation of SPINK5. Br J Dermatol. 2005:152:159-65.
Godic A, Dragos V. Successful treatment of Netherton’s syndrome with topical calcipotriol. Eur J Dermatol. 2004:14:115-7.
Sprecher, E, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton Syndrome: Implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol. 2001; 117(2): 179-187.
Chavanas, S, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton Syndrome. Nat Genet. 2000; 25: 141-142.
Judge, MR, Morgan , G, Harper, JI. A clinical and immunological study of Netherton’s syndrome. Br J Dermatol. 1994; 131: 615-21.
Williams, ML, et al. Genetically Transmitted, Generalized Disorders of Cornification. The Ichthyoses. Dermatol Clin. January 1987; 5(1): 155-78.
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/No patient organizations found related to this disease state.